0000000000702422
AUTHOR
Esther Ballester Asensio
Medición objetiva y percepción subjetiva de los niveles de actividad física en una muestra de niños escolares
El sedentarismo durante la infancia y adolescencia repercute directamente en los niveles de salud de la población. La actividad física se relaciona con una disminución del riesgo de obesidad e hígado graso y mejoría del perfil cardiometabólico en general, mayor masa ósea y fuerza muscular, e incremento en el desarrollo cognitivo a edades tempranas. Con este fin se ha recomendado la práctica de actividad física de intensidad moderada y/o vigorosa al menos durante 60 minutos diarios en niños mayores de 5 años, habiéndose desarrollado diversas guías para población infantil. Diferentes estudios demuestran unos niveles de sedentarismo altos siendo las niñas más sedentarias que los niños, y un cu…
How bilastine is used to treat allergic rhinitis and urticaria in children
Management guidelines for allergic rhinitis and urticaria recommend oral second-generation antihistamines as first-line treatment. The efficacy and safety of bilastine, the newest nonsedating second-generation antihistamine, are well established in adolescents/adults with these allergic conditions. The bilastine development program for pediatric use (2–<12 years) followed EMA-authorized processes. Pharmacokinetic/pharmacodynamic simulation and modeling and a pharmacokinetic study were conducted to identify and confirm the pediatric dose (10 mg/day). A Phase III, multicenter, double-blind, randomized, placebo-controlled, parallel-group study was performed to confirm the safety of bilasti…
Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma
BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow-up. The primary outcome was the evolution of…